Curated News
By: NewsRamp Editorial Staff
August 19, 2026
Quantum BioPharma's Lucid-MS Targets Myelin Repair in MS, Phase 2 Trial Ahead
TLDR
- Quantum BioPharma's Lucid-MS targets myelin degradation, offering a novel approach that could outpace traditional MS therapies and capture market share.
- Lucid-MS preserves myelin and supports functional recovery by targeting degradation, with Phase 2 trials underway after favorable Phase 1 safety results.
- By addressing smoldering lesions and PIRA, Lucid-MS aims to slow MS progression and improve quality of life for patients beyond current treatments.
- Quantum BioPharma's collaboration with Mass General uses PET imaging to visualize myelin integrity, a cutting-edge technique for tracking MS therapy efficacy.
Impact - Why it Matters
This news matters because multiple sclerosis affects millions worldwide, and current treatments often fail to prevent long-term disability progression. Quantum BioPharma's Lucid-MS offers a novel approach that could not only stop disease progression but also potentially restore function by repairing myelin. If successful in clinical trials, it could represent a paradigm shift in MS treatment, offering hope for patients who have limited options. Additionally, the development of PET imaging to assess myelin integrity could improve diagnosis and monitoring of MS, leading to better personalized care.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead drug candidate, Lucid-MS, as a potential new treatment for multiple sclerosis (MS) that targets the underlying mechanism of myelin degradation rather than broadly suppressing the immune system. The company highlights that current therapies may not adequately address progression independent of relapse activity (PIRA), which is linked to chronic active 'smoldering' lesions and compartmentalized inflammation in the central nervous system. By focusing on preserving myelin and supporting functional recovery, Lucid-MS offers a novel approach that could fill a critical gap in MS treatment. Quantum BioPharma has collaborated with Massachusetts General Hospital to develop PET imaging to assess myelin integrity, and has received clearance to initiate a Phase 2 trial following Phase 1 studies that showed a favorable safety profile in healthy volunteers.
Quantum BioPharma is a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative, metabolic, and alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., it is developing Lucid-MS, which has demonstrated in preclinical models the ability to prevent and reverse myelin degradation. The company also invented UNBUZZD(TM), an OTC product for alcohol misuse, and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.48% stake and royalty payments. This news is disseminated on behalf of Quantum BioPharma, and the full article is available at https://ibn.fm/UPeUg. For more information, visit the company's newsroom at https://ibn.fm/QNTM.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Lucid-MS Targets Myelin Repair in MS, Phase 2 Trial Ahead
